Irina Gromova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9267929/publications.pdf

Version: 2024-02-01

67 4,147 37 63 g-index

68 68 68 68 6521

times ranked

citing authors

docs citations

all docs

#	Article	IF	Citations
1	Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Letters, 2000, 480, 2-16.	1.3	291
2	Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin puncta assay. Autophagy, 2015, 11, 1408-1424.	4.3	281
3	Proteomic Characterization of the Interstitial Fluid Perfusing the Breast Tumor Microenvironment. Molecular and Cellular Proteomics, 2004, 3, 327-344.	2.5	278
4	HERC2 coordinates ubiquitin-dependent assembly of DNA repair factors on damaged chromosomes. Nature Cell Biology, 2010, 12, 80-86.	4.6	239
5	Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. Cancer Cell, 2018, 33, 1078-1093.e12.	7.7	238
6	Identification of Extracellular and Intracellular Signaling Components of the Mammary Adipose Tissue and Its Interstitial Fluid in High Risk Breast Cancer Patients. Molecular and Cellular Proteomics, 2005, 4, 492-522.	2.5	200
7	New technique for uncoupling the cleavage and religation reactions of Eukaryotic Topoisomerase I Journal of Molecular Biology, 1991, 222, 669-678.	2.0	150
8	DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biology, 2016, 17, 185.	3.8	140
9	Human and mouse proteomic databases: novel resources in the protein universe. FEBS Letters, 1998, 430, 64-72.	1.3	139
10	IKAP localizes to membrane ruffles with filamin A and regulates actin cytoskeleton organization and cell migration. Journal of Cell Science, 2008, 121, 854-864.	1.2	90
11	Upâ€regulated Proteins in the Fluid Bathing the Tumour Cell Microenvironment as Potential Serological Markers for Early Detection of Cancer of the Breast. Molecular Oncology, 2010, 4, 65-89.	2.1	88
12	Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. Journal of Molecular Biology, 1992, 228, 1025-1030.	2.0	81
13	Specificity and Functional Significance of DNA Interaction with the Nuclear Matrix: New Approaches to Clarify the Old Questions. International Review of Cytology, 1996, 162B, 405-448.	6.2	81
14	The channels model of nuclear matrix structure. BioEssays, 1995, 17, 443-450.	1.2	78
15	Human 2-D PAGE databases for proteome analysis in health and disease: http://biobase.dk/cgi-bin/celis. FEBS Letters, 1996, 398, 129-134.	1.3	75
16	A comprehensive protein ressource for the study of bladder cancer: http://biobase.dk/cgi-bin/celis. Electrophoresis, 1999, 20, 300-309.	1.3	68
17	Human Xip1 (C2orf13) Is a Novel Regulator of Cellular Responses to DNA Strand Breaks. Journal of Biological Chemistry, 2007, 282, 19638-19643.	1.6	68
18	Tumor interstitial fluid \hat{a} €" A treasure trove of cancer biomarkers. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 2259-2270.	1.1	64

#	Article	IF	CITATIONS
19	Proteomic Strategies to Reveal Tumor Heterogeneity among Urothelial Papillomas. Molecular and Cellular Proteomics, 2002, 1, 269-279.	2.5	56
20	Human <i>BLCAP</i> transcript: new editing events in normal and cancerous tissues. International Journal of Cancer, 2010, 127, 127-137.	2.3	56
21	Proteomic Profiling of Mammary Carcinomas Identifies C7orf24, a γ-Glutamyl Cyclotransferase, as a Potential Cancer Biomarker. Journal of Proteome Research, 2010, 9, 3941-3953.	1.8	55
22	Long-range Fragmentation of the Eukaryotic Genome by Exogenous and Endogenous Nucleases Proceeds in a Specific Fashion via Preferential DNA Cleavage at Matrix Attachment Sites. Journal of Biological Chemistry, 1995, 270, 18685-18690.	1.6	50
23	Profiling of micro <scp>RNA</scp> s in tumor interstitial fluid of breast tumors – a novel resource to identify biomarkers for prognostic classification and detection of cancer. Molecular Oncology, 2017, 11, 220-234.	2.1	50
24	bc10: A novel human bladder cancer-associated protein with a conserved genomic structure downregulated in invasive cancer. International Journal of Cancer, 2002, 98, 539-546.	2.3	48
25	Immediate and Delayed Effects of E-Cadherin Inhibition on Gene Regulation and Cell Motility in Human Epidermoid Carcinoma Cells. Molecular and Cellular Biology, 2005, 25, 9138-9150.	1.1	48
26	Molecular pathology of breast apocrine carcinomas: A protein expression signature specific for benign apocrine metaplasia. FEBS Letters, 2006, 580, 2935-2944.	1.3	48
27	Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics. Oncolmmunology, 2016, 5, e1248015.	2.1	48
28	Towards discovery-driven translational research in breast cancer. FEBS Journal, 2004, 272, 2-15.	2.2	45
29	Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer. Molecular and Cellular Proteomics, 2010, 9, 161-177.	2.5	45
30	Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research. Molecular and Cellular Proteomics, 2003, 2, 369-377.	2.5	44
31	Human proteomic databases: a powerful resource for functional genomics in health and disease. Progress in Biophysics and Molecular Biology, 2002, 80, 3-22.	1.4	43
32	Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a wellâ€defined cohort. Molecular Oncology, 2009, 3, 220-237.	2.1	43
33	Identification of true differentially expressed mRNAs in a pair of human bladder transitional cell carcinomas using an improved differential display procedure. Electrophoresis, 1999, 20, 241-248.	1.3	42
34	Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I. Nucleic Acids Research, 1993, 21, 593-600.	6.5	41
35	Proteomic Profiling of Triple-negative Breast Carcinomas in Combination With a Three-tier Orthogonal Technology Approach Identifies Mage-A4 as Potential Therapeutic Target in Estrogen Receptor Negative Breast Cancer. Molecular and Cellular Proteomics, 2013, 12, 381-394.	2.5	40
36	DNA-specific antiidiotypic antibodies in the sera of patients with autoimmune diseases. FEBS Letters, 1992, 314, 259-263.	1.3	38

#	Article	IF	CITATIONS
37	Protein Profiling of the Human Epidermis from the Elderly Reveals Up-regulation of a Signature of Interferon- \hat{I}^3 -induced Polypeptides That Includes Manganese-superoxide Dismutase and the p85 \hat{I}^2 Subunit of Phosphatidylinositol 3-Kinase. Molecular and Cellular Proteomics, 2003, 2, 70-84.	2.5	38
38	Impact of proteomics on bladder cancer research. Pharmacogenomics, 2004, 5, 381-394.	0.6	37
39	TIMP-1 Increases Expression and Phosphorylation of Proteins Associated with Drug Resistance in Breast Cancer Cells. Journal of Proteome Research, 2013, 12, 4136-4151.	1.8	36
40	High level PHGDH expression in breast is predominantly associated with keratin 5â€positive cell lineage independently of malignancy. Molecular Oncology, 2015, 9, 1636-1654.	2.1	34
41	Apocrine Cysts of the Breast. Molecular and Cellular Proteomics, 2006, 5, 462-483.	2.5	33
42	Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Molecular Oncology, 2007, $1,97-119$.	2.1	32
43	A single lysis solution for the analysis of tissue samples by different proteomic technologies. Molecular Oncology, 2008, 2, 368-379.	2.1	31
44	15-Prostaglandin Dehydrogenase Expression Alone or in Combination with ACSM1 Defines a Subgroup of the Apocrine Molecular Subtype of Breast Carcinoma. Molecular and Cellular Proteomics, 2008, 7, 1795-1809.	2,5	31
45	Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics. Oncolmmunology, 2019, 8, e1537691.	2.1	27
46	Omicsâ€based profiling of carcinoma of the breast and matched regional lymph node metastasis. Proteomics, 2008, 8, 5038-5052.	1.3	26
47	Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: Relationship between CK15+ progenitor/amplified cells and preâ€malignant lesions and invasive disease. Molecular Oncology, 2007, 1, 321-349.	2.1	24
48	Tissue proteomics of the human mammary gland: Towards an abridged definition of the molecular phenotypes underlying epithelial normalcy. Molecular Oncology, 2010, 4, 539-561.	2.1	24
49	<i>N</i> â€glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome. Molecular Oncology, 2018, 12, 972-990.	2.1	24
50	Protein Detection in Gels by Silver Staining A Procedure Compatible with Mass Spectrometry. , 2006, , 219-223.		23
51	A Combined Proteome and Ultrastructural Localization Analysis of 14-3-3 Proteins in Transformed Human Amnion (AMA) Cells. Molecular and Cellular Proteomics, 2008, 7, 1225-1240.	2.5	23
52	FABP7 and HMGCS2 Are Novel Protein Markers for Apocrine Differentiation Categorizing Apocrine Carcinoma of the Breast. PLoS ONE, 2014, 9, e112024.	1.1	23
53	A novel member of the glycosyltransferase family, ?3Gn-T2, highly downregulated in invasive human bladder transitional cell carcinomas. Molecular Carcinogenesis, 2001, 32, 61-72.	1.3	22
54	Decreased Camptothecin Sensitivity of the Stem-Cell-Like Fraction of Caco2 Cells Correlates with an Altered Phosphorylation Pattern of Topoisomerase I. PLoS ONE, 2014, 9, e99628.	1.1	22

#	Article	IF	CITATIONS
55	Gaining insights into cancer biology through exploration of the cancer secretome using proteomic and bioinformatic tools. Expert Review of Proteomics, 2017, 14, 1021-1035.	1.3	21
56	Let-7 microRNA controls invasion-promoting lysosomal changes via the oncogenic transcription factor myeloid zinc finger-1. Oncogenesis, 2018, 7, 14.	2.1	20
57	Highâ€throughput proteomics of breast cancer interstitial fluid: identification of tumor subtypeâ€specific serologically relevant biomarkers. Molecular Oncology, 2021, 15, 429-461.	2.1	19
58	Molecular and diagnostic features of apocrine breast lesions. Expert Review of Molecular Diagnostics, 2015, 15, 1011-1022.	1.5	14
59	Proteomic analysis of tissue samples in translational breast cancer research. Expert Review of Proteomics, 2014, 11, 285-302.	1.3	12
60	Human rab11a: transcription, chromosome mapping and effect on the expression levels of host GTP-binding proteins. FEBS Letters, 1998, 429, 359-364.	1.3	11
61	Proteomic strategies in bladder cancer: From tissue to fluid and back. Proteomics - Clinical Applications, 2008, 2, 974-988.	0.8	11
62	Characterization of DNA Topoisomerase \hat{ll}^2 Heterodimers in HeLa Cells. Biochemistry, 1998, 37, 16645-16652.	1.2	9
63	Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer. PLoS ONE, 2017, 12, e0188827.	1.1	9
64	Immunoexpression Analysis and Prognostic Value of BLCAP in Breast Cancer. PLoS ONE, 2012, 7, e45967.	1.1	8
65	Characterization of the Tumor Secretome from Tumor Interstitial Fluid (TIF). Methods in Molecular Biology, 2016, 1459, 231-247.	0.4	7
66	Proteomic analysis of urinary fibrinogen degradation products in patients with urothelial carcinomas. Clinical Proteomics, 2006, 2, 45-65.	1.1	4
67	Proteomic Analysis by Two-Dimensional Polyacrylamide Gel Electrophoresis. , 2006, , 19-46.		1